Robert Solomon, MD
Cardiovascular Disease · Ann Arbor, MINPI 1316309099
Payments from drug & device makers
Across 31 payments — averaging $86.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Cardiva Medical, Inc.$168
- Esperion Therapeutics, Inc.$125
- Amgen$118
- AstraZeneca$75
- Boston Scientific$39
- plus $38 from 2 others
What the payments were for
- Travel & lodging$1,27448%
- Food & beverage$1,07840%
- Education$31712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 20 | $2,107 |
| Cardiva Medical, Inc. | 3 | $168 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Amgen | 2 | $118 |
| AstraZeneca | 1 | $75 |
| Boston Scientific | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,265
- ENSITE$242
- NEXLIZET$125
- NEXLETOL$125
- Cardiva VASCADE 6/7F VCS$123
- OPTIS$122
- Repatha$106
How this compares
$2,669 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 27 | $568,411 |
| JardianceEmpagliflozin | 48 | $50,318 |
| EliquisApixaban | 29 | $35,005 |
| EntrestoSacubitril/Valsartan | 17 | $20,547 |
| Repatha SureclickEvolocumab | 20 | $10,376 |
| Bumetanide | 22 | $1,184 |
| Spironolactone | 49 | $661 |
| Metoprolol Succinate | 41 | $556 |
| Atorvastatin Calcium | 18 | $432 |
| Rosuvastatin Calcium | 16 | $326 |
| Torsemide | 12 | $304 |
| Amiodarone Hcl | 11 | $261 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $250 |
| Potassium Chloride | 13 | $247 |
| Losartan Potassium | 20 | $232 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Ann Arbor
- Stanley ChetcutiAnn Arbor$4.3M
- Victor MolesAnn Arbor$2.1M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Vallerie McLaughlinAnn Arbor$1.4M
- David BachAnn Arbor$390K
- Bertram PittAnn Arbor$298K
- Adam HelmsAnn Arbor$236K
- Salim HayekAnn Arbor$229K
- Brahmajee NallamothuAnn Arbor$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.